PI3K p110beta/delta Inhibitor CVL237 clinical trials
Its developmentBy Convalife (Shanghai) and Karus Therapeutics, step by step4 company-led studies, furthest phase 3: when each phase was reached, its deals, target and what is ahead.How each study uses PI3K p110beta/delta Inhibitor CVL237 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the PI3K p110beta/delta Inhibitor CVL237 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2016 (1)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Convalife (Shanghai) Co., Ltd. (3) · Karus Therapeutics Limited (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses PI3K p110beta/delta Inhibitor CVL237 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Single-arm, Open-label, Multicenter, Phase Ib/II Clinical Trial of CVL237 Tablets in Combination With Serplulimab Injection for the Treatment of Advanced Solid Tumors With PTEN Loss or Low ExpressionNot yet recruitingPhase 2Convalife (Shanghai) Co., Ltd.NCT07446049Written as CVL237 tablets
- CVL237 Tablets for APDS/PASLINot yet recruitingPhase 2/3Convalife (Shanghai) Co., Ltd.NCT06293716Written as CVL237 tablets
- CVL237 Tablets in the Treatment of Advanced Solid Tumors With PTEN DeficiencyNot yet recruitingPhase 2Convalife (Shanghai) Co., Ltd.NCT06183736Written as CVL237 tablets
- The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110β/δ Inhibitor) In B Cell LymphomaCompletedPhase 1Karus Therapeutics LimitedNCT02679196Written as KA2237